
- /
- Supported exchanges
- / US
- / OMER.NASDAQ
Omeros Corporation (OMER NASDAQ) stock market data APIs
Omeros Corporation Financial Data Overview
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Omeros Corporation data using free add-ons & libraries
Get Omeros Corporation Fundamental Data
Omeros Corporation Fundamental data includes:
- Net Revenue: -30 004 000
- EBITDA: -164 158 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Omeros Corporation News

Lobbying Update: $20,000 of OMEROS CORPORATION lobbying was just disclosed
$20,000 of OMEROS CORPORATION lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "General monitoring of health care issues"...


Top Midday Decliners
Omeros (OMER) said it signed agreements to exchange $70.5 million of 2026 convertible notes for new PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...

Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade
Hidden gems often remain undiscovered within the labyrinth of the stock market. Three stocks with massive upside stand out among the several alternatives as possible titans with significant upside pot...

3 Sleeper Stocks Under $15 Ready to Explode by 2029
In general, high-growth stocks and sleeper stocks under $15 are associated with valuation concerns. Let’s forget inflated giants and overhyped darlings. Today, the article reveals three hidden gems....
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.